SCHEMBL6210010

SCHEMBL6210010

CCCCCCCN(CCCCCCSc1nc2cccc(C(=O)OC)c2o1)C(=O)Nc1c(C(C)C)cccc1C(C)C

nearest known ligand 0.72

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
SOAT1 P35610 3/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6283338 0.91 SOAT1 (0.53) SOAT1
SCHEMBL6284663 0.91 SOAT1 (0.51) SOAT1
SCHEMBL6273884 0.85 SOAT1 (0.70) SOAT1
SCHEMBL6210198 0.84 SOAT1 (0.73) SOAT1
SCHEMBL6216107 0.83 SOAT1 (0.57) SOAT1
SCHEMBL6213326 0.79 SOAT1 (0.70) SOAT1
SCHEMBL6215799 0.78 SOAT1 (0.54) SOAT1
SCHEMBL6211191 0.78 SOAT1 (0.57) SOAT1
Dimethylamine SCHEMBL6213621 0.77 SOAT1 (0.68) SOAT1
SCHEMBL6213617 0.77 SOAT1 (0.70) SOAT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1020451-B1 ANILIDE COMPOUNDS AND DRUGS CONTAINING THE SAME KOWA CO (JP) 2005-06-15 EP disclosed
US-6797717-B2 ACYL COENZYME A CHOLESTEROL ACYLTRANSFERASE (ACAT) INHIBITORS KOWA COMPANY, LTD. (JP) 2004-09-28 US disclosed
US-20030087928-A1 Novel anilide compounds and drugs containing the same KOWA COMPANY, LTD., JAPAN 2003-05-08 US disclosed
US-20020099074-A1 Novel anilide compounds and drugs containing the same KOWA COMPANY, LTD.,JAPAN 2002-07-25 US disclosed
US-6362208-B1 ANTICHOLESTEROL AGENT KOWA COMPANY, LTD. (JP) 2002-03-26 US disclosed
EP-1020451-A1 NOVEL ANILIDE COMPOUNDS AND DRUGS CONTAINING THE SAME Kowa Co., Ltd. (JP) 2000-07-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030087928-A1 Novel anilide compounds and drugs containing the same ACAT1, ACAT2, LCAT SOAT1 4/4885
US-20020099074-A1 Novel anilide compounds and drugs containing the same SOAT1, SOAT2, LCAT SOAT1 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.